Wang Liwei, Clinical oncologist
- Specialization: Clinical oncologist
- 40 years of experience
- Speaks:Chinese
- Workplace: China, Qionghai, Boao International Medical Center
- Led China’s first expert consensus on pancreatic cancer diagnosis and treatment and the development of the CSCO Guidelines for Pancreatic Cancer.
Dr. Wang Liwei is a specially appointed expert in medical oncology. He serves as Chief Physician, Level II Professor, and Doctoral Supervisor. He is Director of Oncology at Renji Hospital and a Shanghai Leading Talent. He was an early advocate of MDT, tumor genomics, and personalized therapy. His work centers on gastrointestinal cancers, including pancreatic and biliary tract tumors. He also manages complex cases such as cancers of unknown primary and multiple primary malignancies.
He led China’s first pancreatic cancer expert consensus. He also led the CSCO Pancreatic Cancer Guidelines and renal-protection guidance. He is President of the Yangtze River Delta Oncology Alliance. He was the inaugural Chair of the CSCO Pancreatic Cancer Committee. He heads the National Pancreatic Tumor Study Group.
He is the principal investigator of seven NSFC projects, including a Major Program. He has led two national Major New Drug Innovation and Development projects. He serves as an associate editor or editorial board member for leading journals. He has published more than 100 SCI-indexed papers.
How are we doing?
Qualifications
Professional Profile:
• Specially Appointed Expert in Medical Oncology;
• Chief Physician, Level II Professor of Clinical Oncology, and Doctoral Supervisor.
• Director of the Department of Oncology at Renji Hospital, Shanghai Jiao Tong University School of Medicine, and a Shanghai Leading Talent.
• One of the early advocates in China of multidisciplinary team (MDT) approaches to cancer care, tumor genomics, and personalized treatment.
Clinical Expertise:
• Specializes in gastrointestinal malignancies, including pancreatic cancer, biliary tract tumors, and gastrointestinal cancers.
• Experienced in precision, individualized, and comprehensive management of complex malignancies, including cancers of unknown primary origin and multiple primary malignancies.
Academic Appointments:
• Led the development of China’s first expert consensus on pancreatic cancer diagnosis and treatment, the Chinese Society of Clinical Oncology (CSCO) Guidelines for Pancreatic Cancer, and technical guidelines for renal protection in patients with cancer.
• President of the Yangtze River Delta Oncology Alliance, inaugural Chair of the CSCO Pancreatic Cancer Committee, and Head of the National Pancreatic Tumor Study Group.
Research & Achievements:
• Principal investigator of seven National Natural Science Foundation of China projects, including a Major Program, and two major national projects under the Major New Drug Innovation and Development initiative.
• Associate editor or editorial board member of several leading international and Chinese academic journals. Has published more than 100 SCI-indexed papers.
You may also be interested
Payment & Rewards
You don’t pay for our services
You make your payment directly at the clinic or to their official bank account.
Some clinics may require a deposit as a part of their policy.
Spread out your payments with installment options.
Earn rewards for referring friends to Bookimed.